Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406 · see citing works

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · see citing works

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works

Hepatocellular carcinoma

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055 · see citing works

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974 · see citing works

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · see citing works

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497 · see citing works

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,549 · see citing works

Mechanisms of NAFLD development and therapeutic strategies

Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · see citing works

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · see citing works

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805 · see citing works

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,657 · see citing works

Inflammation, metaflammation and immunometabolic disorders

Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · see citing works

Hepatocellular carcinoma

Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427 · see citing works

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,416 · see citing works

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Abou‐Alfa, G. K., Meyer, T., Cheng, A., El-Khoueiry, A. B., Rimassa, L., Ryoo, B., Çiçin, İ., Merle, P., Chen, Y.-H., Park, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,347 · see citing works

Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116 · see citing works

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxı̀, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,986 · see citing works

Molecular therapies and precision medicine for hepatocellular carcinoma

Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,948 · see citing works

Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children

Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883 · see citing works

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855 · see citing works

Immunotherapies for hepatocellular carcinoma

Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · see citing works

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789 · see citing works

Resolving the fibrotic niche of human liver cirrhosis at single-cell level

Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · see citing works

Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression

Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · see citing works

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708 · see citing works

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Zhu, A. X., Kang, Y., Yen, C., Finn, R. S., Galle, P. R., Llovet, J. M., Assénat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,666 · see citing works

Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576 · see citing works

Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells

Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508 · see citing works

Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H. H., Dufour, J., Lammert, F., Duarte‐Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,507 · see citing works

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483 · see citing works

From NASH to HCC: current concepts and future challenges

Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · see citing works

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · see citing works

Genetic landscape and biomarkers of hepatocellular carcinoma

Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325 · see citing works

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294 · see citing works

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P. J., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,248 · see citing works

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · see citing works

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · see citing works

Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis

Tzartzeva, K., Obi, J., Rich, N. E., Parikh, N. D., Marrero, J. A., Yopp, A., Waljee, A. K., & Singal, A. G. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.064 · Cited by 1,207 · see citing works

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029349 · Cited by 1,146 · see citing works

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124 · see citing works

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106 · see citing works

Senolytic CAR T cells reverse senescence-associated pathologies

Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098 · see citing works

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders

Aron‐Wisnewsky, J., Vigliotti, C., Witjes, J. J., Le, P. T., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,085 · see citing works

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044 · see citing works

Classification and characterization of microsatellite instability across 18 cancer types

Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 982 · see citing works

The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941 · see citing works

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Yau, T. (., Park, J. W. (.-W., Finn, R. S. (. S. )., Cheng, A. L. (.-L., Mathurin, P., Edeline, J., Kudo, M. (., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · Cited by 934 · see citing works

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Kanwal, F., Kramer, J. R., Asch, S. M., Chayanupatkul, M., Cao, Y., & El‐Serag, H. B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.012 · Cited by 931 · see citing works

Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth

Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923 · see citing works

Lipotoxicity and the gut-liver axis in NASH pathogenesis

Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847 · see citing works

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Zhu, A. X., Park, J. O., Ryoo, B., Yen, C.-J., Poon, R. T. P., Pastorelli, D., Blanc, J., Chung, H. C., Baron, A. D., Pfiffer, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 845 · see citing works

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Bruix, J., Raoul, J., Sherman, M., Mazzaferro, V., Bolondi, L., Craxı̀, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822 · see citing works

The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence

El‐Serag, H. B., Hampel, H., & Javadi, F. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.007 · Cited by 821 · see citing works

Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease

Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795 · see citing works

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793 · see citing works

Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis

Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784 · see citing works

Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review

White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766 · see citing works

NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., et al. (2016) · Nature · doi:10.1038/nature16969 · Cited by 766 · see citing works

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00523-4 · Cited by 757 · see citing works

Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma

Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719 · see citing works

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma

Salem, R., Gordon, A. C., Mouli, S. K., Hickey, R., Kallini, J. R., Gabr, A., Mulcahy, M. F., Baker, T., Abecassis, M. M., Miller, F. H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.029 · Cited by 696 · see citing works

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development

Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688 · see citing works

Fibrosis and cancer: A strained relationship

Piersma, B., Hayward, M.-K., & Weaver, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188356 · Cited by 686 · see citing works

A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease

Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 683 · see citing works

Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes

Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678 · see citing works

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676 · see citing works

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01868-2 · Cited by 652 · see citing works

Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease

Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648 · see citing works

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

Garin, É., Tselikas, L., Guiu, B., Chalaye, J., Edeline, J., de Baère, T., Assénat, E., Tacher, V., Robert, C., Terroir-Cassou-Mounat, M., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30290-9 · Cited by 639 · see citing works

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · see citing works

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604 · see citing works

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team

Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.011 · Cited by 603 · see citing works

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity

Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589 · see citing works

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer

Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583 · see citing works

Immune cell-mediated features of non-alcoholic steatohepatitis

Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573 · see citing works

Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma

Wahl, D. R., Stenmark, M. H., Tao, Y., Pollom, E. L., Caoili, E. M., Lawrence, T. S., Schipper, M. J., & Feng, M. U.-S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4925 · Cited by 568 · see citing works

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study

Salem, R., Johnson, G. E., Kim, E., Riaz, A., Bishay, V. L., Boucher, É., Fowers, K. D., Lewandowski, R. J., & Padia, S. A. (2021) · Hepatology · doi:10.1002/hep.31819 · Cited by 568 · see citing works

Carriage of the PNPLA3 rs738409 C &gt;G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma

Liu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549 · see citing works

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer

Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538 · see citing works

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00326-6 · Cited by 535 · see citing works

Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis

Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., Salati, M., Dottorini, L., Iaculli, A., Varricchio, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3520 · Cited by 530 · see citing works

ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development

Nakagawa, H., Umemura, A., Taniguchi, K., Font-Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Valasek, M. A., Seki, E., Hidalgo, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.001 · Cited by 525 · see citing works

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

Seki, S., Kitada, T., Yamada, T., Sakaguchi, H., Nakatani, K., & Wakasa, K. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00073-9 · Cited by 523 · see citing works

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

Dudek, M., Pfister, D., Donakonda, S., Filpe, P., Schneider, A., Laschinger, M., Hartmann, D., Hüser, N., Meiser, P., Bayerl, F., et al. (2021) · Nature · doi:10.1038/s41586-021-03233-8 · Cited by 512 · see citing works

Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy

Papatheodoridis, G., Chan, H. L., Hansen, B. E., Janssen, H. L. A., & Lampertico, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.002 · Cited by 511 · see citing works

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.003 · Cited by 499 · see citing works

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498 · see citing works

Coffee, Decaffeinated Coffee, and Tea Consumption in Relation to Incident Type 2 Diabetes Mellitus

Huxley, R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.439 · Cited by 471 · see citing works

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

Singal, A. G., Zhang, E. D., Narasimman, M., Rich, N. E., Waljee, A. K., Hoshida, Y., Yang, J. D., Reig, M., Cabibbo, G., Nahon, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.023 · Cited by 455 · see citing works

Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis

Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sánchez, W. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.10.005 · Cited by 452 · see citing works

Fibrosis-dependent mechanisms of hepatocarcinogenesis

Zhang, D. Y., & Friedman, S. L. (2012) · Hepatology · doi:10.1002/hep.25670 · Cited by 444 · see citing works

Cafestol and Kahweol, Two Coffee Specific Diterpenes with Anticarcinogenic Activity

Cavin, C., Holzhaeuser, D., Scharf, G., Constable, A., Huber, W. W., & Schilter, B. (2002) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(02)00029-7 · Cited by 422 · see citing works

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview

Parthasarathy, G., Revelo, X. S., & Malhi, H. (2020) · Hepatology Communications · doi:10.1002/hep4.1479 · Cited by 420 · see citing works

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407 · see citing works

Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma

Gomes, A. L., Teijeiro, A., Burén, S., Tummala, K. S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., & Djouder, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.020 · Cited by 401 · see citing works

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398 · see citing works

Effect of Metformin on Metabolic Improvement and Gut Microbiota

Lee, H., & Ko, G. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01357-14 · Cited by 387 · see citing works

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores

Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385 · see citing works

Adaptive immunity: an emerging player in the progression of NAFLD

Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374 · see citing works

Epidemiology and risk-stratification of NAFLD-associated HCC

Ioannou, G. N. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.012 · Cited by 361 · see citing works

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review

Loomba, R. S., Lim, J. K., Patton, H. M., & El‐Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 360 · see citing works

A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma

Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355 · see citing works

Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases

Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.14937 · Cited by 336 · see citing works

Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis

Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D., & Singal, A. G. (2021) · Hepatology · doi:10.1002/hep.31309 · Cited by 333 · see citing works

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts

Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1321-x · Cited by 317 · see citing works

Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study

Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313 · see citing works

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis

Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00078-x · Cited by 307 · see citing works

Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality

Simon, T. G., Duberg, A., Aleman, S., Chung, R. T., Chan, A. T., & Ludvigsson, J. F. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912035 · Cited by 304 · see citing works

The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation

BasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302 · see citing works

Pharmacotherapy for NASH: Current and emerging

Konerman, M. A., Jones, J. C., & Harrison, S. A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 293 · see citing works

Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis

BasuRay, S., Wang, Y., Šmagris, Ē., Cohen, J. C., & Hobbs, H. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901974116 · Cited by 285 · see citing works

Therapeutic pipeline in nonalcoholic steatohepatitis

Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278 · see citing works

NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.

Foerster, F., Gairing, S., Müller, L., & Galle, P. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.007 · Cited by 265 · see citing works

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M. V., Miele, L., Petta, S., Maier, S., Rosso, C., Luca, L. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 262 · see citing works

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial

Cheng, A., Guan, Z., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Yang, T., Tak, W. Y., Pan, H., Yu, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.006 · Cited by 260 · see citing works

Temporal Trends of Nonalcoholic Fatty Liver Disease–Related Hepatocellular Carcinoma in the Veteran Affairs Population

Mittal, S., Sada, Y. H., El‐Serag, H. B., Kanwal, F., Duan, Z., Temple, S., May, S., Kramer, J. R., Richardson, P., & Davila, J. A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.013 · Cited by 260 · see citing works

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

Pinyol, R., Torrecilla, S., Wang, H., Montironi, C., Piqué‐Gili, M., Torres‐Martín, M., Leow, W. Q., Willoughby, C. E., Ramadori, P., Andreu-Oller, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.049 · Cited by 257 · see citing works

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253 · see citing works

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250 · see citing works

Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?

Febbraio, M. A., Reibe, S., Shalapour, S., Ooi, G., Watt, M. J., & Karin, M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.012 · Cited by 250 · see citing works

Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies

Chen, Y., Wang, X., Wang, J., Yan, Z., & Luo, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.063 · Cited by 248 · see citing works

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)

Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248 · see citing works

CXCR2 inhibition enables NASH-HCC immunotherapy

Leslie, J., Mackey, J. B. G., Jamieson, T. J., Ramon‐Gil, E., Drake, T. M., Fercoq, F., Clark, W. A., Gilroy, K. L., Hedley, A., Nixon, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326259 · Cited by 225 · see citing works

Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling

Liang, Q., Teoh, N., Xu, L., Pok, S., Li, X., Chu, E. S., Chiu, J., Dong, L., Arfianti, A., Haigh, W. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06931-6 · Cited by 223 · see citing works

Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma

Zheng, L., Yang, W. K., Wu, F., Wang, C., Yu, L., Tang, L., Qiu, B., Li, Y., Guo, L., Wu, M.-C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0203 · Cited by 218 · see citing works

Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression

Orci, L. A., Sanduzzi-Zamparelli, M., Caballol, B., Sapena, V., Colucci, N., Torres, F., Bruix, J., Reig, M., & Toso, C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.002 · Cited by 218 · see citing works

The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma

Polesel, J., Zucchetto, A., Montella, M., Maso, L. D., Crispo, A., Vecchia, C. L., Serraino, D., Franceschi, S., & Talamini, R. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn565 · Cited by 210 · see citing works

Failure Rates in the Hepatocellular Carcinoma Surveillance Process

Singal, A. G., Yopp, A. C., Gupta, S. N., Skinner, C. S., Halm, E. A., Okolo, E., Nehra, M. S., Lee, W. M., Marrero, J. A., & Tiro, J. A. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0046 · Cited by 209 · see citing works

Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease

Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020) · Hepatology · doi:10.1002/hep.30858 · Cited by 209 · see citing works

Smoothened is a master regulator of adult liver repair

Michelotti, G. A., Xie, G., Swiderska, M., Choi, S. S., Karaca, G., Krüger, L., Premont, R. T., Yang, L., Syn, W., METZGER, D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66904 · Cited by 208 · see citing works

XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis

Deczkowska, A., David, E., Ramadori, P., Pfister, D., Safran, M., Li, B., Giladi, A., Jaitin, D. A., Barboy, O., Cohen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01344-3 · Cited by 197 · see citing works

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

Younes, R., Caviglia, G. P., Govaere, O., Rosso, C., Armandi, A., Sanavia, T., Pennisi, G., Liguori, A., Francione, P., Gallego-Durán, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.008 · Cited by 196 · see citing works

Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification

Ioannou, G. N., Green, P. K., Kerr, K. F., & Berry, K. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.008 · Cited by 191 · see citing works

Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose–response meta-analysis

Kennedy, O. J., Roderick, P. J., Buchanan, R. M., Fallowfield, J. A., Hayes, P. C., & Parkes, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013739 · Cited by 190 · see citing works

Convergent somatic mutations in metabolism genes in chronic liver disease

Ng, S. W. K., Rouhani, F. J., Brunner, S. F., Brzozowska, N., Aitken, S. J., Yang, M., Abascal, F., Moore, L., Nikitopoulou, E., Chappell, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03974-6 · Cited by 190 · see citing works

The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups

Chitturi, S., Wong, V. W., Chan, W., Wong, G. L., Wong, S. K., Sollano, J. D., Ni, Y., Liu, C., Lin, Y., Lesmana, L. A., et al. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13856 · Cited by 182 · see citing works

Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes

Zhang, X., Harmsen, W. S., Mettler, T. A., Kim, W. R., Roberts, R. O., Therneau, T. M., Roberts, L. R., & Chaiteerakij, R. (2014) · Hepatology · doi:10.1002/hep.27199 · Cited by 181 · see citing works

MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase

Cao, Z., Fan-Minogue, H., Bellovin, D. I., Yevtodiyenko, A., Arzeno, J., Yang, Q., Gambhir, S. S., & Felsher, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3367 · Cited by 179 · see citing works

Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease

Fuchs, A. G., Samovski, D., Smith, G. I., Cifarelli, V., Farabi, S. S., Yoshino, J., Pietka, T., Chang, S.-W., Ghosh, S., Myckatyn, T. M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.008 · Cited by 163 · see citing works

Long-Term Treatment With Cisapride and Antibiotics in Liver Cirrhosis: Effect on Small Intestinal Motility, Bacterial Overgrowth, and Liver Function

Madrid, A. M., Hurtado, C., Venegas, M., Cumsille, F., & Defilippi, C. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03636.x · Cited by 158 · see citing works

Inhibition of Autophagy Enhances Anticancer Effects of Atorvastatin in Digestive Malignancies

Yang, P., Liu, Y.-L., Lin, Y.-C., Shun, C., Wu, M., & Chen, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1626 · Cited by 155 · see citing works

rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

Teo, K., Abeysekera, K. W. M., Adams, L. A., Aigner, E. S., Anstee, Q. M., Bañales, J. M., Banerjee, R., Basu, P., Berg, T., Bhatnagar, P., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.027 · Cited by 154 · see citing works

Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease

Gangarapu, V., İnce, A. T., Baysal, B., Kayar, Y., Klç, U., Gök, Ö., Uysal, Ö., & Şentürk, H. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000348 · Cited by 153 · see citing works

Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid

Dunham, R. M., Thapa, M., Velazquez, V. M., Elrod, E. J., Denning, T. L., Pulendran, B., & Grakoui, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201937 · Cited by 145 · see citing works

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.09.005 · Cited by 145 · see citing works

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers

Kawaguchi, T., Shima, T., Mizuno, M., Mitsumoto, Y., Umemura, A., Kanbara, Y., Tanaka, S., Sumida, Y., Yasui, K., Takahashi, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0185490 · Cited by 144 · see citing works

Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD

Wabitsch, S., McCallen, J., Kamenyeva, O., Ruf, B., McVey, J. C., Kabát, J., Walz, J. S., Rotman, Y., Bauer, K. C., Craig, A. J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.010 · Cited by 144 · see citing works

Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development

Brown, Z. J., Fu, Q., Ma, C., Kruhlak, M. J., Zhang, H., Luo, J., Heinrich, B., Yu, S. J., Zhang, Q., Wilson, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0687-6 · Cited by 142 · see citing works

Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention

Lange, N. F., Radu, P., & Dufour, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.025 · Cited by 137 · see citing works

Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis

Schoenberger, H., Chong, N., Fetzer, D. T., Rich, N. E., Yokoo, T., Khatri, G., Olivares, J., Parikh, N. D., Yopp, A. C., Marrero, J. A., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.012 · Cited by 135 · see citing works

Angiopoietin‐2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease

Lefere, S., de Velde, F. V., Hoorens, A., Raevens, S., Campenhout, S. V., Vandierendonck, A., Neyt, S., Vandeghinste, B., Vanhove, C., Debbaut, C., et al. (2018) · Hepatology · doi:10.1002/hep.30294 · Cited by 134 · see citing works

Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study

Gawrieh, S., Dakhoul, L., Miller, E., Scanga, A. E., deLemos, A. S., Kettler, C. D., Burney, H. N., Liu, H., Abu‐Sbeih, H., Chalasani, N., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15464 · Cited by 130 · see citing works

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids

Prill, S., Caddeo, A. M., Baselli, G., Jamialahmadi, O., Dongiovanni, P., Rametta, R., Kanebratt, K. P., Pujia, A., Pingitore, P., Mancina, R. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47737-w · Cited by 123 · see citing works

Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: an updated systematic review of 81 epidemiological studies

Abdel-Rahman, O., Helbling, D., Schöb, O., Eltobgy, M., Mohamed, H., Schmidt, J., giryes, A., Mehrabi, A., Iype, S., John, H., et al. (2017) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12270 · Cited by 118 · see citing works

The coffee-specific diterpenes cafestol and kahweol protect against aflatoxin B1-induced genotoxicity through a dual mechanism

Cavin, C. (1998) · Carcinogenesis · doi:10.1093/carcin/19.8.1369 · Cited by 115 · see citing works

Diabetes Mellitus and Poorer Prognosis in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Wang, Y., Wang, P., Wang, B., Fu, Z., Zhao, W., & Yan, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095485 · Cited by 113 · see citing works

Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease

Kramer, J. R., Natarajan, Y., Dai, J., Yu, X., Li, L., El‐Serag, H. B., & Kanwal, F. (2021) · Hepatology · doi:10.1002/hep.32244 · Cited by 113 · see citing works

Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis

Zhu, C., Tabas, I., Schwabe, R. F., & Pajvani, U. B. (2021) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-020-00365-6 · Cited by 112 · see citing works

The genomic landscape of Mongolian hepatocellular carcinoma

Candia, J., Bayarsaikhan, E., Tandon, M., Budhu, A., Forgues, M., Товуу, Л.-О., Tudev, U., Lack, J., Chao, A., Chinburen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18186-1 · Cited by 110 · see citing works

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Qin, S., Chen, Z., Fang, W. J., Ren, Z., Xu, R., Ryoo, B., Meng, Z., Bai, Y., Chen, X., Liu, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.383 · Cited by 108 · see citing works

Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma

Tanaka, S., Miyanishi, K., Kobune, M., Kawano, Y., Hoki, T., Kubo, T., Hayashi, T., Sato, T., Sato, Y., Takimoto, R., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-012-0739-0 · Cited by 107 · see citing works

Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda

Singal, A. G., Lok, A. S.-F., Feng, Z., Kanwal, F., & Parikh, N. D. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.036 · Cited by 106 · see citing works

Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study

Chong, N., Schoenberger, H., Yekkaluri, S., Fetzer, D. T., Rich, N. E., Yokoo, T., Gopal, P., Manwaring, C., Quirk, L., & Singal, A. G. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16779 · Cited by 104 · see citing works

Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models

Coulon, S., Legry, V., Heindryckx, F., Steenkiste, C. V., Casteleyn, C. R., Olievier, K., Libbrecht, L. J., Carmeliet, P., Jonckx, B., Stassen, J., et al. (2013) · Hepatology · doi:10.1002/hep.26219 · Cited by 101 · see citing works

Hepatocellular carcinoma in a mouse model fed a choline‐deficient, L‐amino acid‐defined, high‐fat diet

Ikawa‐Yoshida, A., Matsuo, S., Kato, A., Ohmori, Y., Higashida, A., Kaneko, E., & Matsumoto, M. (2017) · International Journal of Experimental Pathology · doi:10.1111/iep.12240 · Cited by 99 · see citing works

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma

Jühling, F., Hamdane, N., Crouchet, É., Shen, L., Saghire, H. E., Mukherji, A., Fujiwara, N., Oudot, M. A., Thumann, C., Saviano, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318918 · Cited by 98 · see citing works

Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study

Baumeister, S. E., Schlesinger, S., Aleksandrova, K., Jochem, C., Jenab, M., Gunter, M. J., Overvad, K., Tjønneland, A. M., Boutron‐Ruault, M., Carbonnel, F., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.014 · Cited by 96 · see citing works

Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs

Roudier, E. A., Mistafa, O., & Stenius, U. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0352 · Cited by 92 · see citing works

Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2)

Majer, B. J., Hofer, E., Cavin, C., Lhoste, E. F., Uhl, M., Glatt, H. R., Meinl, W., & Knasmüller, S. (2005) · Food and Chemical Toxicology · doi:10.1016/j.fct.2004.11.009 · Cited by 90 · see citing works

Hepatocellular Carcinoma — Origins and Outcomes

Kelley, R. K., & Greten, T. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2106594 · Cited by 90 · see citing works

Inhibitory Effects of Chlorogenic Acid, Reserpine, Polyprenoic Acid (E-5166), or Coffee on Hepatocarcinogenesis in Rats and Hamsters

Tanaka, T., Nishikawa, A., Shima, H., Sugie, S., Shinoda, T., Yoshimi, N., Iwata, H., & Mori, H. (1990) · Springer eBooks · doi:10.1007/978-1-4615-9561-8_45 · Cited by 89 · see citing works

Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma

Zhou, Y., Zhu, G., Liu, T., Zheng, J.-N., Cheng, Z., Zou, T., Braddock, M., Fu, S., & Zheng, M. (2016) · Scientific Reports · doi:10.1038/srep33743 · Cited by 86 · see citing works

Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor

Sutter, A. P., Maaser, K., Höpfner, M., Huether, A., Schuppan, D., & Scherübl, H. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.010 · Cited by 85 · see citing works

Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice

Heinrich, B., Brown, Z. J., Diggs, L. P., Vormehr, M., Ma, C., Subramanyam, V., Rosato, U., Ruf, B., Walz, J. S., McVey, J. C., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.09.031 · Cited by 82 · see citing works

The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease

Daugherity, E. K., Balmus, G., Saei, A. A., Moore, E. S., Abdallah, D. S. A., Rogers, A. B., Weiss, R. S., & Maurer, K. J. (2012) · Cell Cycle · doi:10.4161/cc.20259 · Cited by 81 · see citing works

Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene

Tan, H., Zain, S. M., Mohamed, R. B., Rampal, S., Chin, K. F., Basu, R. C., Cheah, P., Mahadeva, S., & Mohamed, Z. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0850-x · Cited by 81 · see citing works

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

Greten, T. F., Abou‐Alfa, G. K., Cheng, A., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002794 · Cited by 81 · see citing works

Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis

Kwak, M., Mehaffey, J. H., Hawkins, R. B., Hsu, A., Schirmer, B. D., & Hallowell, P. T. (2019) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2019.09.006 · Cited by 75 · see citing works

Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes

Natarajan, Y., Kramer, J. R., Yu, X., Li, L., Thrift, A. P., El‐Serag, H. B., & Kanwal, F. (2020) · Hepatology · doi:10.1002/hep.31157 · Cited by 74 · see citing works

Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice

Ou, R., Liu, J., Lv, M., Wang, J., Wang, J., Zhu, L. Y., Zhao, L., & Xu, Y. (2017) · Endocrine · doi:10.1007/s12020-017-1323-4 · Cited by 73 · see citing works

Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study

Fassio, E., Díaz, S. V., Santa, C., et al. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31681-3 · Cited by 65 · see citing works

T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis

Ramadori, P., Kam, S., & Heikenwalder, M. (2022) · Hepatology · doi:10.1002/hep.32336 · Cited by 64 · see citing works

Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease

Wong, C. R., Njei, B. M., Nguyen, M. H., Nguyen, A., & Lim, J. K. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14342 · Cited by 58 · see citing works

Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK

Relja, B. (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.892 · Cited by 57 · see citing works

Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

Koh, Y. X., Tan, H. J., Liew, Y. X., Syn, N. L. X., Teo, J. Y., Lee, S. Y., Goh, B. K. P., Goh, G. B., & Chan, C. Y. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.07.012 · Cited by 55 · see citing works

Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH

Jadhav, K. S., & Cohen, T. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592157 · Cited by 53 · see citing works

Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades

Puigvehí, M., Hashim, D., Haber, P. K., Dinani, A. M., Schiano, T. D., Asgharpour, A., Kushner, T., Kakked, G. A., Tabrizian, P., Schwartz, M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15576 · Cited by 52 · see citing works

Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection

Su, C., Chau, G., Hung, H. H., Yeh, Y., Lei, H., Hsia, C., Lai, C., Lin, H., & Wu, J. C. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4221-5 · Cited by 47 · see citing works

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

Jian, J., Nie, M., Xiang, B., Qian, H., Yin, C., Zhang, X., Zhang, M. H., Zhu, X., & Xie, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841132 · Cited by 47 · see citing works

Improved survival outcomes in patients with non‐alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002–2012 U nited N etwork for O rgan S haring data

Wong, R. J., Chou, C., Bonham, C. A., Concepcion, W., Esquivel, C. O., & Ahmed, A. (2014) · Clinical Transplantation · doi:10.1111/ctr.12364 · Cited by 46 · see citing works

Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression

Kah, J., Wüstenberg, A., Keller, A. D., Sirma, H., Montalbano, R., Ocker, M., Volz, T., Dandri, M., Tiegs, G., & Sass, G. (2012) · Oncology Reports · doi:10.3892/or.2012.1860 · Cited by 46 · see citing works

Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects

Lei, H., Reinke, P., Volk, H., Lv, Y., & Wu, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02667 · Cited by 44 · see citing works

Loss of hepatocyte cell division leads to liver inflammation and fibrosis

Dewhurst, M. R., Ow, J. R., Zafer, G., van Hul, N. K. M., Wollmann, H., Bisteau, X., Brough, D., Choi, H., & Kaldis, P. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1009084 · Cited by 42 · see citing works

Treatment Candidacy for Pharmacologic Therapies for NASH

Rowe, I. A., Wong, V. W.-S., & Loomba, R. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.005 · Cited by 41 · see citing works

Glucokinase Regulatory Protein Genetic Variant Interacts with Omega-3 PUFA to Influence Insulin Resistance and Inflammation in Metabolic Syndrome

Pérez‐Martínez, P., Delgado‐Lista, J., García‐Ríos, A., Monagle, J. M., Gulseth, H. L., Ordovás, J. M., Shaw, D. I., Karlström, B., Kieć‐Wilk, B., Blaak, E. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020555 · Cited by 39 · see citing works

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391 · see citing works

Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC

Huang, Y., Xie, Y., Zhang, Y., Liu, Z., Jiang, W., Ye, Y., Tang, J., Li, Z., Yin, Z., & Lin, X.-J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02370-2 · Cited by 41 · see citing works

The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC

Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32 · see citing works

Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis

Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T. (2025) · Liver Cancer · doi:10.1159/000548536 · Cited by 2 · see citing works

Prevalence of fatty liver in metabolic syndrome

Goyal, A., Arora, H., & Arora, S. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1108_19 · Cited by 17 · see citing works

Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?

Montecucco, F., & Mach, F. (2008) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153008786848268 · Cited by 17 · see citing works

Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease

Cheng, Y.-L., Wang, Y.-J., Lan, K.-H., Huo, T.-I., Huang, Y.-H., Su, C.-W., Hsieh, W., Hou, M.-C., Lin, H.-C., Lee, F., et al. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/9279836 · Cited by 27 · see citing works

Features of myocardial damage indexes in patients with metabolic syndrome and nonalcoholic fatty liver disease

Собирова, Г. Н., Uzokov, J., Bafoeva, Z. O., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2021.155040 · Cited by 1 · see citing works

Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease

Vyas, K. Y., & Patel, J. K. (2019) · Indian Practitioner